Agree on all fronts. I think dropping out of ASX hasn't helped here and the lower volumes over the last 4-8 weeks show that there's less interest. For me, this is largely the reason to discontinue coverage and Morningstar have just sunk the boot in on the way out. I don't agree with all of the analyst's comments (today or in June/July) and believe she is basing these entirely off of the Feb result. She basically says that E4 is the only potential good thing in the pipeline and this isn't the case. Nuvaring will add significant revenues as will other pipeline generics with no/low competition (another WH product with market size 200M). The Novast deal is also good and allows us to play in another 500M combined market. If the results on Friday are somewhat stable, the outlook more promising and some FDA approvals start dropping (there are two that could be any day now) then we are back in business and this will attract some attention. Fingers crossed for all.
MYX Price at posting:
36.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)